Excedrin

Excedrin is a consumer healthcare brand of over-the-counter pain relievers used primarily for headaches and migraine symptoms. Its best-known formulation combines acetaminophen, aspirin, and caffeine. Acetaminophen contributes analgesic and fever-reducing effects, aspirin provides analgesic and anti-inflammatory effects, and caffeine is used as an adjunct that may enhance pain relief and constrict dilated blood vessels associated with some headaches. Because the active ingredients have different pharmacological roles, the brand has historically presented the combination as a multi-mechanism approach to difficult headache pain. The brand was introduced by Bristol-Myers in 1960 as Excedrin Extra Strength. It was described as an early multi-ingredient headache treatment and originally contained 250 milligrams each of acetaminophen and aspirin, together with 65 milligrams of caffeine per tablet. The formulation was later revised, with the last reported change to the Extra Strength formula occurring in 1978. Excedrin subsequently expanded beyond a single general-purpose headache product into a portfolio organized around particular consumer-described pain conditions and usage occasions. A major extension arrived in 1969 with Excedrin PM, a combination of acetaminophen and diphenhydramine citrate intended to address headache pain alongside sleep. In 1998, the U.S. Food and Drug Administration cleared Excedrin Migraine for nonprescription relief of migraine headache pain and associated symptoms. Although Excedrin Migraine used the same active ingredients and strengths as the established Extra Strength formula, its positioning made it one of the first migraine medicines marketed to consumers without a prescription. Later products included Excedrin Tension Headache, Excedrin Sinus Headache, and the caffeine-free Excedrin Back & Body. Excedrin became particularly recognizable through advertising that framed severe headaches as “Excedrin headaches,” later using the expression “Excedrin tension headaches.” This communication strategy associated the brand with especially intense or disruptive headache experiences rather than routine minor aches. The brand also used condition-specific naming to distinguish products for migraine, tension headache, sinus discomfort, and body pain. Some products, including Excedrin Menstrual Complete, were discontinued. Ownership changed several times. Bristol-Myers Squibb sold its North American consumer medicines business, including Excedrin, to Novartis in 2005 for $660 million. In 2015, Excedrin became part of the consumer-health joint-venture arrangement between Novartis and GlaxoSmithKline, with GSK holding the majority ownership described in the reference material. On July 18, 2022, GSK separated its consumer-health business into Haleon, and Excedrin became part of Haleon’s portfolio. The brand has also experienced significant supply and quality events. In January 2012, Novartis voluntarily recalled selected bottle configurations because of the possibility of stray tablets from other Novartis products and broken or chipped tablets. In January 2020, GSK temporarily stopped production and distribution of selected Excedrin Extra Strength and Excedrin Migraine caplets and gel tabs after identifying inconsistencies in ingredient transfer and weighing processes. In December 2020, approximately 400,000 bottles were recalled over concerns that holes in the bottle bottoms could allow children to gain access to the medicine. These events affected availability and consumer handling but did not end the brand. Excedrin is principally associated with the U.S. market; it is no longer sold in Canada, where earlier Canadian products used formulations different from those sold in the United States.

Excedrin emerged from Bristol-Myers’ consumer medicines business in 1960 with the launch of Excedrin Extra Strength. The product used a three-ingredient combination of acetaminophen, aspirin, and caffeine, an approach that became central to the brand’s identity. The combination allowed Excedrin to distinguish itself from single-ingredient pain relievers and to describe its product as addressing headache pain through complementary mechanisms. The Extra Strength formulation was subsequently modified, with the last reported formula change taking place in 1978. The brand broadened its scope in 1969 through Excedrin PM, which combined acetaminophen with diphenhydramine citrate. This product linked headache relief with a sleep-aid function and represented an early move toward products designed for a specific consumer situation rather than for pain in general. Excedrin later applied similar segmentation to named headache types. In 1998, Excedrin Migraine received U.S. regulatory clearance for nonprescription relief of migraine headache pain and associated symptoms. Its active ingredients and strengths matched those of the regular Extra Strength product, but its migraine-specific labeling and marketing made it a significant positioning development for the brand. Further extensions included Excedrin Tension Headache in 2003 and Excedrin Sinus Headache in 2005. Excedrin Tension Headache used acetaminophen and caffeine, while Excedrin Sinus Headache paired acetaminophen with phenylephrine hydrochloride. In 2007, the brand moved into a broader body-pain proposition with Excedrin Back & Body, a caffeine-free formulation containing acetaminophen and aspirin. The product was presented as working both as a pain reliever and as a pain blocker at the site of discomfort. Other condition-oriented products were introduced over time, including Excedrin Menstrual Complete, which was later discontinued. Advertising was an important part of Excedrin’s development. Campaigns in the 1970s described exceptionally unpleasant headaches as “Excedrin headaches,” and later communications used “Excedrin tension headaches.” The phrase helped make the brand synonymous with severe headache experiences and gave the product a clear emotional and functional territory. The later introduction of Excedrin Migraine continued this strategy by attaching the brand to a recognized headache condition and by emphasizing consumer access without a prescription. Corporate ownership shifted in the 2000s and 2010s. In 2005, Bristol-Myers Squibb sold its North American consumer medicine business, including Excedrin, to Novartis for $660 million. The transaction reflected Bristol-Myers Squibb’s effort to concentrate on selected higher-priority prescription-medicine areas. In 2015, Excedrin entered the consumer-health joint-venture structure created by Novartis and GlaxoSmithKline, with GSK holding the majority ownership described in the available reference. GSK later separated its consumer-health operations, and on July 18, 2022, those operations became Haleon. Excedrin therefore moved from Bristol-Myers to Novartis, then into the Novartis-GSK consumer-health arrangement, and finally into Haleon. The brand’s history also includes several quality and supply disruptions. Novartis announced a voluntary recall in January 2012 covering selected bottle configurations with specified expiration dates because of the possibility of mixed tablets or damaged tablets. In January 2020, GSK stopped production and distribution of selected Excedrin Extra Strength and Excedrin Migraine caplets and gel tabs after discovering inconsistencies in the transfer and weighing of ingredients. In December of the same year, a recall involving roughly 400,000 bottles addressed the possibility that holes in container bottoms could provide children access to the medicine. Excedrin remains an active over-the-counter brand, principally associated with the United States, while it is no longer sold in Canada.

• 2022

  Brand transferred to Haleon

  [1]Excedrin (brand)en.wikipedia.org

  Excedrin became part of Haleon when GSK separated its consumer-health business.

• 2020

  Production temporarily halted

  [1]Excedrin (brand)en.wikipedia.org

  GSK temporarily stopped production and distribution of selected Excedrin Extra Strength and Excedrin Migraine forms following quality-control findings.

• 2020

  Bottle-packaging recall announced

  [1]Excedrin (brand)en.wikipedia.org

  Approximately 400,000 bottles were recalled because holes in some containers could allow children to access the medicine.

• 2015

  Excedrin enters Novartis-GSK consumer-health joint venture

  [1]Excedrin (brand)en.wikipedia.org

  Excedrin became part of the consumer-health joint-venture arrangement in which GSK held majority ownership.

• 2012

  Selected products recalled

  [1]Excedrin (brand)en.wikipedia.org

  Novartis voluntarily recalled selected Excedrin bottle configurations because of possible mixed or damaged tablets.

• 2007

  Excedrin Back & Body introduced

  [1]Excedrin (brand)en.wikipedia.org

  The brand extended into back and body pain with a caffeine-free acetaminophen-and-aspirin product.

• 2005

  Excedrin Sinus Headache introduced

  [1]Excedrin (brand)en.wikipedia.org

  Excedrin expanded into sinus-related headache positioning with a formulation containing acetaminophen and phenylephrine hydrochloride.

• 2005

  Bristol-Myers Squibb sells consumer medicines business

  [1]Excedrin (brand)en.wikipedia.org

  Bristol-Myers Squibb sold its North American consumer medicines business, including Excedrin, to Novartis.

• 2003

  Excedrin Tension Headache introduced

  [1]Excedrin (brand)en.wikipedia.org

  The brand introduced a product specifically named and marketed for tension headaches.

• 1998

  Excedrin Migraine cleared for nonprescription marketing

  [1]Excedrin (brand)en.wikipedia.org

  The FDA cleared Excedrin Migraine for relief of migraine headache pain and associated symptoms, making it an important consumer-facing extension of the brand.

• 1978

  Last reported Extra Strength formula change

  [1]Excedrin (brand)en.wikipedia.org

  The reference identifies 1978 as the year of the last change to the Excedrin Extra Strength formulation.

• 1969

  Excedrin PM launched

  [1]Excedrin (brand)en.wikipedia.org

  Excedrin PM combined acetaminophen with diphenhydramine citrate, pairing headache treatment with a sleep-aid component.

• 1960

  Excedrin Extra Strength introduced

  [1]Excedrin (brand)en.wikipedia.org

  Bristol-Myers introduced Excedrin Extra Strength as a multi-ingredient headache treatment containing acetaminophen, aspirin, and caffeine.

A mass-market over-the-counter pain-relief brand positioned around difficult headaches, migraine symptoms, and targeted pain occasions. Its core differentiation is the use of combination formulas and condition-specific product names, supported historically by advertising focused on unusually severe headaches.

• Headache analgesic · 1960

  Excedrin Extra Strength

  The foundational Excedrin product, introduced in 1960 for headache relief. Its signature formulation combines acetaminophen, aspirin, and caffeine. The product established the brand’s multi-ingredient positioning and served as the reference point for later condition-specific variants.

• Nighttime headache analgesic · 1969

  Excedrin PM

  Introduced in 1969, Excedrin PM combines acetaminophen with diphenhydramine citrate. It was positioned as a combined headache-relief and sleep-aid product and helped establish Excedrin’s practice of addressing a particular usage occasion.

• Migraine analgesic · 1998

  Excedrin Migraine

  A migraine-labeled over-the-counter product cleared for marketing in 1998. It uses the same reported active ingredients and strengths as the traditional Extra Strength product but presents them specifically for migraine headache pain and associated symptoms.

• Tension-headache analgesic · 2003

  Excedrin Tension Headache

  Introduced in 2003 for tension-headache positioning. The reported formula contains acetaminophen and caffeine, extending the brand’s condition-specific approach beyond its general headache product.

• Sinus-headache medicine · 2005

  Excedrin Sinus Headache

  Introduced in 2005 as a product for sinus-related headache symptoms. Its reported ingredients are acetaminophen and phenylephrine hydrochloride, combining pain relief with a decongestant component.

• Body-pain analgesic · 2007

  Excedrin Back & Body

  Introduced in 2007 as a caffeine-free product for back and body pain. The reported formula contains acetaminophen and aspirin, and the product was marketed around a dual pain-relief proposition.

• Menstrual-pain analgesic

  Excedrin Menstrual Complete

  A discontinued condition-specific product. The reference states that it used the same active ingredients as Excedrin Extra Strength and Excedrin Migraine, despite being marketed for menstrual symptoms.

• 1998Excedrin is now Excedrin Migraine

  United States

  At the launch of Excedrin Migraine, advertising emphasized that the new migraine product contained the same active ingredients as Excedrin Extra Strength while presenting the medicine for a specific headache condition.

  Outcome. Extended the brand into consumer migraine treatment and condition-specific marketing.

  Source
• 1970Excedrin headaches

  United States

  Excedrin advertising in the 1970s described particularly unpleasant or severe headaches as “Excedrin headaches,” linking the brand to intense headache experiences.

  Outcome. Helped establish the brand’s distinctive severe-headache positioning.

  Source

• 2022

  Transfer to HaleonM&A

  Background

  GSK separated its consumer healthcare operations from the rest of the group.

  Action taken

  Excedrin was transferred into Haleon when the consumer healthcare business was spun off on July 18, 2022.

  Aftermath

  Haleon became the brand’s owner and operating consumer-health company.

  Source

• 2020

  Temporary production stoppage for selected productsOther

  Background

  Routine quality-control and assurance procedures found inconsistencies in the transfer and weighing of ingredients.

  Action taken

  GSK temporarily stopped production and distribution of selected Excedrin Extra Strength and Excedrin Migraine caplets and gel tabs.

  Aftermath

  GSK said production was expected to restart, but it did not provide a definite resumption date at the time of the announcement.

  Source

• 2020

  Recall over bottle-bottom holesOther

  Background

  Some bottles were alleged to have holes in their bottoms, creating a risk that children could gain access to the caplets.

  Action taken

  Approximately 400,000 bottles across several package sizes were recalled.

  Aftermath

  The recall focused on preventing accidental pediatric access and potential overdose or poisoning.

  Source

• 2012

  Voluntary recall of selected Excedrin configurationsOther

  Background

  Novartis identified a possibility that some packages contained tablets or capsules from other products, or contained broken or chipped tablets.

  Action taken

  Novartis recalled selected bottle configurations, instructed distribution partners to stop distribution, and asked consumers to stop using affected products.

  Aftermath

  The company announced that product shipments would resume later in 2012.

  Source

• 2005

  Sale of Excedrin to NovartisM&A

  Background

  Bristol-Myers Squibb decided to sell its North American consumer medicines business as part of a strategy to concentrate on selected profitable disease areas.

  Action taken

  The consumer medicines business, including Excedrin, was sold to Novartis.

  Aftermath

  Excedrin moved from Bristol-Myers Squibb’s consumer portfolio into Novartis’s over-the-counter medicines business.

  Transaction value. $660 million (2005 transaction)

  Source

1. 1Excedrin (brand)en.wikipedia.org